Poolbeg Pharma oral vaccine programme advancing through non-dilutive funding

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, has announced an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation Fund in November 2022, as part of the Poolbeg led EncOVac Consortium[1]. Having finalised the research plan and all consortium members completing the Consortium and Grant Agreements, the EncOVac Consortium parties are now entering the next phase to commence the validation of the encapsulation process. The validation is expected to complete in H2 2023.

Taking place over three years, the EncOVac Consortium is funded to develop a Phase I clinical trial ready oral vaccine candidate. The agreed research plan includes several stages of work and once the encapsulation process, developed by AnaBio Technologies, has been successfully validated, the consortium will proceed to encapsulate vaccine antigen candidates developed by Associate Professor Siobhán McClean at University College Dublin (‘UCD’) together with adjuvants identified by Professor Ed Lavelle at Trinity College Dublin. This oral vaccine candidate will then complete all required non-clinical testing in preparation for a Phase I clinical trial.

Poolbeg’s Oral Vaccine Programme will possess the capability to generate vaccines for a wide range of diseases and represents a significant commercial opportunity. The platform has the potential to be licensed to partners or developed internally within Poolbeg, positioning the Company to help tackle a broad range of infectious diseases, which has the potential to make a positive impact on public health.

Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg, commented“The validation of the encapsulation process is a key step in the creation of a Phase I clinical trial ready oral vaccine candidate and Poolbeg is proud to lead the EncOVac Consortium. Delivering oral vaccines to the gut has the potential to revolutionise global protection against infectious disease. In contrast to intramuscular vaccines that generate systemic immunity, oral vaccines induce mucosal immunity, which can induce better protection against pathogens at the site of infection.”

Dr. Aidan Fitzsimons, Chief Executive Officer of AnaBio Technologies, remarked “This is a very exciting step in the development of next generation vaccines. With the EncOVac consortium, and in partnership with Poolbeg, UCD and Trinity, we can develop effective oral vaccine candidates that can provide a more accessible and efficient solution to preventing a range of infectious diseases.”

Associate Professor Siobhán McClean, UCD School of Biomolecular and Biomedical Science, said, “Having worked in the fields of chronic infection and vaccine development for many years, this consortium has the potential to be immensely beneficial for the development of oral vaccines. By triggering mucosal immunity, we can target the areas where pathogens enter the body, resulting in more effective and long-lasting protective responses, benefitting both patients and public healthcare systems.”

Professor Ed Lavelle, Professor of Vaccine Immunology at Trinity College Dublin, added “The COVID-19 pandemic has highlighted the need for innovative approaches to vaccine development. The EncOVac consortium’s focus on oral vaccines has the potential to address the key challenges associated with vaccination against mucosal pathogens by inducing local immune responses at the site of infection. By developing an effective oral vaccine candidate, we can improve accessibility and reduce the burden on healthcare systems, while also providing more effective protection against infectious diseases.”

[1] The EncOVac consortium is led by Poolbeg in partnership with AnaBio Technologies (‘AnaBio’), University College Dublin (‘UCD’), and Trinity College Dublin (‘Trinity’).

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Share on twitter
Share on linkedin
Poolbeg Pharma

More articles like this

Poolbeg Pharma

Poolbeg Pharma gets go-ahead for Japanese patent

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a notice of

Poolbeg Pharma

AI Unleashed: Experts from Poolbeg Pharma & CytoReason

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington – CEO of

Poolbeg Pharma

Poolbeg Pharma plc granted allowance from the Japanese Patent Office

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. The

Poolbeg Pharma

Poolbeg Pharma patent opposition to be withdrawn

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be

Poolbeg Pharma

AI to revolutionise drug development by 2026

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development, within the

Poolbeg Pharma

Poolbeg Pharma make significant progress in advancing pipeline

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update ·    Strong cash balance

Poolbeg Pharma

Poolbeg Pharma’s Oral Vaccine Platform

By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat,

Poolbeg Pharma

AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma

The potential benefits of AI in the development of medicines

Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on

Poolbeg Pharma

AI will be a game-changer for medicine

Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries. But the use of cutting-edge AI could benefit us all by dramatically speeding up the development

Poolbeg Pharma

The role of generative AI in drug discovery

The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In

Poolbeg Pharma

How is AI transforming drug discovery?

The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping the future of medicine. The pharmaceutical business is

Poolbeg Pharma

AI’s impact on the future of pharma and drug discovery

The recent surge in activity in deploying AI capabilities in pharmaceutical R&D shows no sign of abating, with ‘big pharma’ investing significant capital in streamlining or accelerating the drug discovery process and applying AI methods to identifying new

No more posts to show